Which respiratory advocacy organizations does Leapcure work with?

Leapcure operates an established respiratory advocacy network that includes the American Lung Association, Respiratory Health Association, Breathe Support Network, and One Breath Foundation, alongside grassroots and multilingual groups. These are active, co-developed relationships, not list purchases. COPD-specific partners are being confirmed by our Marketing team and are described generically until they are named and brand-approved.

Can Leapcure recruit COPD patients globally and multilingually?

Yes. On a completed global Phase 2 pulmonary program Leapcure enrolled across 7 countries, and across completed Phase 2 IPF studies it enrolled across 11 countries, running multilingual campaigns and optimizing by region. That multinational respiratory capability applies directly to a global COPD study.

What happens if our COPD trial is behind on enrollment?

Leapcure is built to stabilize enrollment that has stalled. We activate our respiratory advocacy network and pulmonologist engine, run precision digital tuned to an oxygen-dependent population, and pre-screen against complex eligibility so sites receive screen-ready referrals. We track referral quality and site capacity continuously and rebalance channels and geographies toward where enrollment can move fastest, the same approach that kept completed respiratory programs enrolling across multiple countries.

Proven respiratory recruitment, built for Chronic Obstructive Pulmonary Disease (COPD).

Name: Chronic Obstructive Pulmonary Disease Clinical Trial Recruitment | Leapcure
Creator: Leapcure

Leapcure has completed respiratory and pulmonary trials in the same older, oxygen-dependent, travel-burdened population COPD shares. We reach these patients through an established respiratory advocacy network and pulmonologist outreach, then pre-screen against complex eligibility before referral.

Talk to our respiratory team See how it works →

~8,900

Patients pre-screened

completed global Phase 2 pulmonary program, 7 countries

657

Pulmonologists engaged

completed Phase 2 respiratory (IPF) programs

72%

Of sites enrolled a Leapcure patient

completed global Phase 2 pulmonary program, 7 countries

26%

Respiratory paid-search impression share

69% top-of-page, ahead of specialized competitors

Understanding COPD as a Clinical Trial Indication

Chronic obstructive pulmonary disease (COPD) is a progressive obstructive airway disease that makes breathing steadily harder, driven mostly by long-term airway inflammation and emphysema. According to the CDC, more than 16 million US adults have been diagnosed with COPD, and many more are estimated to be living with it undiagnosed. It sits within obstructive airway disease alongside asthma, and its trial population is older, frequently oxygen-dependent, and carries real travel and comorbidity burden.

For sponsors, that population is exactly what makes COPD recruitment hard. Eligible patients are older and often managing multiple conditions, many depend on supplemental oxygen and find travel to sites difficult, and protocols narrow the pool with lung-function thresholds, exacerbation history, and prior-therapy requirements. Generic volume campaigns surface interested patients who then fail eligibility or cannot sustain site visits, wasting coordinator time and stalling enrollment.

Leapcure brings completed respiratory recruitment in this same population: a global Phase 2 pulmonary program that pre-screened roughly 8,900 patients and enrolled across 7 countries, with 72% of sites enrolling at least one Leapcure patient, and two completed Phase 2 IPF studies that recruited an older, oxygen-dependent, travel-burdened population across 11 countries with a screen-fail rate below the study average. Leapcure's respiratory experience spans obstructive airway disease including asthma and COPD. We reach these patients through an established respiratory advocacy network, a pulmonologist outreach engine of 657 engaged physicians, and multilingual global campaigns, then pre-screen against complex eligibility before referral.

The Challenge

COPD recruitment demands more than reach. It demands finding an older, oxygen-dependent, comorbid population and getting them to sites ready to enroll, against eligibility that keeps narrowing the pool.

An older, oxygen-dependent, travel-burdened population

Many COPD patients depend on supplemental oxygen and find long-distance travel to sites difficult, and decisions to join a trial hinge on logistics and whether the family believes it is worth the effort. Recruitment that ignores these realities produces referrals that never screen.

Respiratory experience: across two completed Phase 2 IPF studies, Leapcure recruited this same older, oxygen-dependent, travel-burdened population, with a Patient Success team guiding each patient and caregiver through logistics to enrollment.

Eligibility keeps narrowing an already competitive pool

COPD protocols filter on lung-function thresholds, exacerbation history, smoking status, and prior therapy. Generic digital campaigns surface interested patients who then fail these criteria late, burying coordinators in unqualified referrals while the protocol stalls.

Respiratory experience: on a completed global Phase 2 pulmonary program Leapcure pre-screened roughly 8,900 patients, and on completed Phase 2 IPF studies ran a screen-fail rate of 52% versus a 55% study average by confirming eligibility before referral.

Reaching patients takes trusted respiratory relationships

COPD patients are reached through the communities and clinicians they already trust, not through untargeted advertising alone. Sponsors that rely only on site walk-in and standard digital lose the race for a limited, competed-for pool.

Respiratory experience: Leapcure operates an established respiratory advocacy network and a pulmonologist outreach engine of 657 engaged physicians built across completed respiratory programs.

Global, multilingual enrollment is hard to coordinate

COPD trials increasingly run across multiple countries, where diagnosis pathways, language, and referral behavior vary. Recruitment that cannot operate multilingually and rebalance by region leaves enrollment concentrated in a few sites.

Respiratory experience: Leapcure enrolled across 7 countries on a completed pulmonary program and 11 countries across completed IPF studies, running multilingual campaigns and optimizing by region.

Three channels. One strategy built for your COPD trial.

Leapcure deploys the respiratory recruitment engine it has already run, mapped to your COPD protocol, your sites, your geographies, and your timeline.

Activate respiratory advocacy, digital, and pulmonologist channels

We activate an established respiratory advocacy network, precision digital campaigns across search and respiratory patient communities, and direct pulmonologist engagement, an outreach engine of 657 physicians built on completed respiratory programs. Channel mix is matched to your eligibility criteria, site locations, and oxygen and travel realities.

Pre-screen against complex eligibility before referral

Every patient is engaged before being assigned to a site. We assess protocol eligibility, account for oxygen dependence and travel logistics, and include caregivers where it helps. Sites conduct official screening. We make sure the patients who arrive are informed, eligible, and prepared, the same discipline that ran IPF screen-fail below the study average.

Enroll globally and optimize by region

We run multilingual campaigns and track channel performance and site contact rates continuously across regions, rebalancing advocacy, digital, and physician outreach by referral quality and site capacity. On completed respiratory programs this kept enrollment moving across 7 and 11 countries.

Completed respiratory recruitment in the population COPD shares.

Challenge Context

Our experience

Completed respiratory and pulmonary recruitment in the older, oxygen-dependent, travel-burdened population COPD shares.

Source work (respiratory, completed)

A global Phase 2 pulmonary program and two Phase 2 IPF studies, all completed.

Why it applies to COPD

COPD sits inside obstructive airway disease alongside asthma, and its trial population maps directly onto the population Leapcure already recruited in IPF and pulmonary programs. The recruiting task, reach a hard-to-find respiratory population and confirm eligibility before referral, is the same.

Results & Metrics

Pulmonary reach

On a completed global Phase 2 pulmonary program, roughly 8,900 patients pre-screened and 50+ enrolled across 7 countries, with 72% of sites enrolling at least one Leapcure patient.

IPF recruitment in COPD's population

Across two completed Phase 2 IPF studies, an older, oxygen-dependent, travel-burdened population recruited across 11 countries, with screen-fail 52% versus a 55% study average.

Pulmonologist network

657 pulmonologists engaged across completed respiratory programs, a physician network reusable for COPD.

Respiratory search and AEO leadership

26% respiratory paid-search impression share and 69% top-of-page, ahead of specialized competitors, evidence of presence where high-intent respiratory patients look.

Four channels. Proven in respiratory. Built for COPD.

Leapcure reaches COPD patients through an established respiratory advocacy network, precision digital, pulmonologist outreach, and answer-engine visibility delivered to your trial.

Respiratory Advocacy Network

•An established, active respiratory advocacy network already reaches obstructive airway disease patients, including COPD.
•Named respiratory partners include the American Lung Association, Respiratory Health Association, Breathe Support Network, and One Breath Foundation, alongside grassroots and multilingual groups.
•COPD-specific partners such as dedicated COPD foundations are being confirmed by Marketing and are described generically until named and brand-approved.

Precision Digital Campaigns

•Search, respiratory patient communities, and platform-native advocacy content, targeted by geography, eligibility, and site proximity.
•Messaging and imagery are refined for an older, often oxygen-dependent population, and mapped to site capacity so referrals stay matched to where sites can screen.
•Multilingual campaigns support global COPD enrollment across markets.

Pulmonologist and Patient Success Outreach

•A pulmonologist outreach engine of 657 engaged physicians, built on completed respiratory programs, surfaces diagnosed patients through their treating clinicians.
•A high-touch Patient Success team supports each patient and caregiver through oxygen, travel, and expectations from first contact to enrollment.
•This support is why respiratory referrals arrive informed and ready, reducing screen-fail and coordinator burden.

Answer-Engine and AI-Search Visibility

•COPD patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may be eligible for. We make your trial's information genuinely retrievable for those engines.
•We do this with crawlable, factually rich content, cited sources, and presence in the advocacy and ClinicalTrials.gov sources AI engines actually cite, not schema tricks or content written for machines.
•In respiratory paid search Leapcure reached a 26% impression share and 69% top-of-page, ahead of specialized competitors, evidence of real presence where high-intent patients look.

Built on an established respiratory advocacy network

Leapcure's respiratory advocacy partnerships are active and co-developed, not list purchases. These are respiratory relationships already in place, applied to COPD. COPD-specific partners are being confirmed by Marketing and described generically until approved.

American Lung Association

National lung-health authority and credibility anchor for respiratory outreach, including COPD

Respiratory Health Association

Respiratory-focused advocacy organization reaching obstructive airway disease patients

Breathe Support Network

Patient support network for respiratory disease and a warm referral channel

One Breath Foundation

Respiratory patient and caregiver advocacy supporting trial awareness and trust

COPD-specific partners

Dedicated COPD organizations being confirmed by Marketing, described generically until named and brand-approved

Living with COPD? A clinical trial may be an option.

If you are living with COPD, a clinical trial may give you access to investigational treatments that are not yet widely available. We know COPD makes daily breathing hard, and that travel, oxygen, and energy all factor into any decision. Leapcure's team offers step-by-step support, answers your questions, and includes your family or caregivers wherever that helps.

See if a COPD trial may be right for you

Leapcure has completed respiratory and pulmonary trials in the older, oxygen-dependent, travel-burdened population COPD shares, pre-screening roughly 8,900 patients on one program, enrolling across 7 and 11 countries, engaging 657 pulmonologists, and leading respiratory paid search. We map that respiratory experience directly onto your COPD protocol. Talk to our respiratory team about your active or upcoming COPD study.

Talk to our respiratory team